Stealthy biotech buys up patent portfolios in string of recent deals
Terran Biosciences has emerged from obscurity to snap up slew of IP rights in the past two months
Terran Biosciences has emerged from obscurity to snap up slew of IP rights in the past two months
NortonLifeLock has pledged to appeal the jury verdict, which could balloon to $550 million with enhanced damages for wilful infringement
Following major US CRISPR decision, Michael Arciero, VP of IP at ERS Genomics, tells IAM that tricky patent landscapes are the new normal in biotech
Petro Terblanche tells IAM about the IP issues surrounding her team’s new replica of Moderna’s covid-19 vaccine
10 February 2022
Versatile biotechnologies are changing patterns of collaboration among healthcare innovators
10 February 2022
EPO Board of Appeal seeks clarification on joint applicants approach to priority rights
04 February 2022
The pair say their strategic cooperation will start with in-house patent prosecution services with the potential to grow from there
02 February 2022
Spate of recent transactions show the value of gene-editing patents beyond Cas9
28 January 2022
Even some of the programme’s architects seem to agree that it has strayed from initial focus on trade secrets and intellectual property
22 January 2022
African tech transfer hub is making fast progress in replicating the approved mRNA jab
18 January 2022
Saturday Opinion: In-house leaders say a mooted patent box regime limited to life sciences will reward companies that get patents already, failing to encourage IP investment in new industries
04 December 2021
The deal shows how privacy and silo barriers to the commercialisation of information are being overcome
29 November 2021
Tasuku Honjo’s recent patent battles highlight the potential IP dangers of academic collaborations
18 November 2021
Get unlimited access to all IAM content